IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD Case 1
IMiD Sequencing in Relapsed Multiple Myeloma with Paul G. Richardson, MD
Case Scenario 1:
July 2011
- The patient is a 61-year-old Caucasian female who was diagnosed with stage II MM. Genetic testing showed her to have t(4:16). At the time she was treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy followed by autologous stem cell transplantation.
- She achieved a partial response with RVD and remained in remission. Based on her high-risk cytogenetics, the patient was placed on lenalidomide maintenance therapy.
August 2016
- Routine follow up shows that her M-protein levels have now risen to 1.4 g/dL and her light chain levels continue to rise.
- Although she has developed mild anemia and her creatinine level is slightly elevated to 1.3 mg/dL, she continues to work full-time, has no bone pain, and a has a normal calcium level.
Recent Videos
Related Content
Bridging and BCMA Exposure Impact Ide-Cel Outcomes in Multiple Myeloma
June 9th 2025Article
During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients receiving ide-cel in terms of bridging therapy, quality of life, and prior BCMA therapy.
Read More
